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Editorial: Multidisciplinary success conceals a missed opportunity 
Cordelia E. M. Coltart, W. John Edmunds, Katherine E. Atkins 
 
The 2013–16 Ebola epidemic in West Africa was larger than all previous Ebola outbreaks 
combined and was unique in the breadth of its geographical dispersion. The size and scope of this 
epidemic provided the potential to achieve significant advances in understanding the disease and 
to improve outbreak prevention strategies and public health responses for the future. This special 
issue gathers together research on key aspects of the disease to ensure that lessons can be learned 
and improvements made for the benefit of future responses. It is the first compendium compiled 
addressing the largest Ebola epidemic in history. 
                 
The nature of research into neglected tropical diseases, particularly those which only result in 
occasional outbreaks, is that publication is infrequent. This special issue builds on a 
comprehensive previous special issue published following the second largest outbreak to date in 
Kikwit, Democratic Republic of Congo in 1995. This was published in Journal of Infectious Diseases 
(1999) and contains the key body of scientific work underpinning much of what we knew about 
Ebola prior to the 2013–16 epidemic (1).  
 
This current special issue reflects the multidisciplinary approach required to deal with a global 
health crisis and offers new research to enhance the biological, epidemiological, clinical and 
operational Ebola knowledge-base. Due to the unprecedented scale of cross-national virus 
transmission, we also include dedicated research on the behavioural and socio-political factors 
that both drove and eventually played a part in halting the epidemic. For example, Wilkinson et 
al. (2) provide detailed accounts of the landscape of local outbreak responses which complements 
work by Jalloh et al. (3): a “Knowledges, Attitudes and Practices” survey conducted through the 
epidemic in Sierra Leone and Guinea, the first such study related to Ebola. Additionally, Wenham 
et al. (4) and Ross (5) detail the high-level architecture of outbreak response management.  
 
The most important step forward during the epidemic was the development of a safe and highly 
effective vaccine and this publication includes the first review of the vaccine candidates (Lambe 
et al. (6)). In addition, the use of mathematical modelling and computationally intensive statistical 
techniques has become a mainstay of outbreak control analysis and this work, which has not 
previously been applied to Ebola outbreaks, is reflected in the current issue: e.g. Funk et al. (7) 
and Mbala et al. (8). Whitty (9) highlights the crucial role of integrating such diverse disciplines 
to optimise the outbreak response and he hypothesizes that without this the epidemic would have 
been significantly worse.  
 
On the other hand a key opportunity was missed: this epidemic provided the potential to collect 
enough data over a sufficient period of time to develop, test and implement therapeutic, 
prophylactic and non-pharmaceutical control strategies for Ebola. Previous outbreaks had been 
over too quickly with too few cases to set up rigorously controlled studies, whereas this epidemic 
provided a rare opportunity. However, notwithstanding the significant contribution to future 
disease control of the effective rVSV ZEBOV vaccine that underwent successful phase III clinical 
trials in Guinea (10), insufficient data was gathered to develop clinical knowledge regarding the 
basic supportive management and appropriate therapeutic protocols for Ebola patients. This 
missed opportunity is exemplified by the editors’ inability to commission a clinical research 
article for this special issue. While many factors influencing disease outcome remain elusive, we 
have included a number of papers focused on clinical aspects of the outbreak: Rojek et al. (11) 
review the developments in pharmaceutical therapeutics that occurred during the epidemic and 
suggest barriers to regulatory approval; Garske et al. (12) conduct comprehensive analyses of line 
list data to evaluate predictors of case fatality risk; and Logue et al. (13) provide a case study of 
Ebola diagnostics and training in field laboratories during the outbreak.  
 
Unfortunately, the sparsity of data collected also serves to limit our understanding of the 
effectiveness of different interventions. This in turn restricts our ability to better understand the 
answers to key public health questions such as: which transmission interventions work best?; 
and in which order should they be deployed? It is only through indirect and retrospective 
analysis—e.g. Funk et al. (6), Skrip et al. (13), and Senga et al. (14)—that we can start to address 
these questions given there were no direct observational studies conducted during the epidemic. 
The ineffective implementation of interventions, together with the lack of data, not only 
hampered research efforts but also had a direct effect on the spread of the epidemic. Senga et al. 
estimate that only a small fraction of new cases reported over the first six months were known 
contacts of prior cases (documented on contact tracing lists) meaning that contact tracing in the 
initial stages of the epidemic was highly ineffective. This led to unmonitored, sustained 
transmission that, in all probability, prevented the epidemic from being contained. 
The paucity of data sits in stark contrast to the surge in publications about Ebola that appeared 
during the first year of the crisis as the epidemic ran uncontrolled (Figure). Cori et al. (14) provide 
a comprehensive description of the data and data management techniques we will need to control 
future outbreaks, with an important discussion of the need for rapid transfer of useably formatted 
data to facilitate real time analysis of outbreak control. While resolving this issue was not feasible 
during the 1995 Kikwit outbreak, technological developments by the 2010s meant this should 
not have remained a problem.   
 
Over 20 years after publication of the Kikwit Ebola special issue, woefully little progress has been 
made in controlling and treating Ebola. As Coltart et al. (15) highlight, many of the same concerns 
and conclusions documented in the 1990s by Heymann et al. pursuant to the Kikwit outbreak 
remain relevant now and match the recommendations made by the expert panels reviewing the 
recent epidemic.  This is reinforced by Piot et al. (16) who detail examples of recommendations 
common to both the 1995 and 2013–16 outbreaks including the need for stronger infectious 
disease surveillance (both national and global), improved international preparedness to provide 
support when similar outbreaks occur, more broad-based international health regulations, and 
continued and coordinated Ebola research (diagnostics, patient management, and identification 
of the natural reservoir).  
 
The impact of this epidemic on individuals, healthcare, societies, and economies was profound 
and will last many years beyond the end of the outbreak. Had the lessons of previous outbreaks 
been heeded by the global community, thousands of deaths could have been prevented. Looking 
forward, we sincerely hope that recommendations will be enacted and translated into tangible 
solutions. Although Ebola outbreaks remain inevitable, this can and should prevent future 
outbreaks from reaching the same size and scale as the devastating 2013–16 epidemic.  
 
 
 Fig 1: Number of Ebolavirus cases reported by year (bars) and number of published 
articles containing the word “ebola” by year (points). Labels (black) correspond to 
previous outbreaks where more than 100 cases were reported. Previous special issue 
documenting the outbreak in Kikwit in the Democratic Republic of the Congo (DRC, 
formerly Zaire) time in blue.  
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